Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• Parkinson's disease (PD) affects millions globally, characterized by alpha-synuclein aggregation.
• Alpha-synuclein pathology is implicated in neurotoxic pathways, including lysosomal dysregulation and oxidative stress.
• The protein's cell-to-cell spread contributes to disease progression.

Purpose of the Study:

• To review current therapeutic strategies for Parkinson's disease targeting alpha-synuclein.
• To explore disease-modifying therapies that address multiple facets of alpha-synuclein toxicity.
• To highlight advances in tackling PD onset and progression.

Main Methods:

• Review of current research on therapeutic approaches for Parkinson's disease.
• Analysis of strategies targeting alpha-synuclein spread, production, aggregation, and degradation.
• Examination of receptor blocking, alpha-synuclein reduction, small molecules, immunotherapy, and enhanced degradation.

Main Results:

• Multiple therapeutic avenues are being explored to combat alpha-synuclein toxicity.
• Strategies include blocking alpha-synuclein receptors, reducing its production, inhibiting aggregation, and enhancing its degradation.
• Immunotherapy and lysosomal flux enhancement are promising approaches.

Conclusions:

• Targeting alpha-synuclein offers a promising route for disease-modifying therapies in Parkinson's disease.
• A multi-pronged therapeutic approach addressing various aspects of alpha-synuclein toxicity is likely necessary.
• Future research may yield treatments that significantly impact PD onset and progression.